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Abstract
Background: Clinical characterization of bladder carcinomas is still inadequate using the standard
clinico-pathological prognostic markers. We assessed the correlation between nm23-H1, Rb, EGFR
and p53 in relation to the clinical outcome of patients with muscle invasive bilharzial bladder cancer
(MI-BBC).
Methods: nm23-H1, Rb, EGFR and p53 expression was assessed in 59 MI-BBC patients using
immunohistochemistry and reverse transcription (RT-PCR) and was correlated to the standard
clinico-pathological prognostic factors, patient's outcome and the overall survival (OS) rate.
Results: Overexpression of EGFR and p53 proteins was detected in 66.1% and 35.6%; respectively.
Loss of nm23-H1and Rb proteins was detected in 42.4% and 57.6%; respectively. Increased EGFR
and loss of nm23-H1 RNA were detected in 61.5% and 36.5%; respectively. There was a statistically
significant correlation between p53 and EGFR overexpression (p < 0.0001), nm23 loss (protein and
RNA), lymph node status (p < 0.0001); between the incidence of local recurrence and EGFR RNA
overexpression (p= 0.003) as well as between the incidence of metastasis and altered Rb expression
(p = 0.026), p53 overexpression (p < 0.0001) and mutation (p = 0.04). Advanced disease stage
correlated significantly with increased EGFR (protein and RNA) (p = 0.003 & 0.01), reduced nm23-
H1 RNA (p = 0.02), altered Rb (p = 0.023), and p53 overexpression (p = 0.004). OS rates correlated
significantly, in univariate analysis, with p53 overexpression (p = 0.011), increased EGFR (protein
and RNA, p = 0.034&0.031), nm23-H1 RNA loss (p = 0.021) and aberrations of ≥ 2 genes. However,
multivariate analysis showed that only high EGFR overexpression, metastatic recurrence, high
tumor grade and the combination of ≥ 2 affected markers were independent prognostic factors.
Conclusion: nm23-H1, EGFR and p53 could be used as prognostic biomarkers in MI-BBC patients.
In addition to the standard pathological prognostic factors, a combination of these markers (≥ 2)
has synergistic effects in stratifying patients into variable risk groups. The higher is the number of
altered biomarkers, the higher will be the risk of disease progression and death.
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Background
In Egypt, Schistosoma-associated bladder cancer repre-
sents the commonest malignancy in all diagnosed cancer
cases according to the registry of the National Cancer
Institute, Cairo [1]. To date, several studies have
attempted to identify the spectrum of genetic changes that
occurs during urothelial transformation of bilharzial
bladder cancer (BBC) and to elucidate in detail the natural
history of tumors with different clinical outcome. A
wealth of information about the molecular pathogenesis
of BBC has emerged, including cytogenetic and molecular
genetic analysis via comparative studies on schistosoma-
and non-schistosoma- associated bladder cancers which
demonstrate different clinicopathologic features, patho-
genetic mechanisms and a unique genetic make-up. How-
ever, the clinical significance of these defects either
singular or in combination, is still not clear [2-4].
Some of these studies documented a significant reduction
in disease free survival (DFS) for p53 positive tumors in
BBC and transitional cell carcinoma (TCC) of the western
countries [3,5] Similarly, absence of Rb protein was found
more frequently in tumors with high grade and stage and
was clearly associated with poor clinical outcome [6-9]
However, the examination of data for single markers is
not sufficient to direct clinical decisions for individual
patients [4].
The nm23-H1 gene (NME1), localized on chromosome
17q21.3 was first isolated as a metastasis suppressor gene
by differential screening of cDNA library from high and
low metastatic clones of a murine melanoma cell line
[10]. The clinical relevance of the nm23-H1 as a metastasis
suppressor for human cancers including bladder is still
controversial. Some studies demonstrated that nm23-H1
is inversely correlated with tumor staging, histological dif-
ferentiation and clinical outcome [11,12], others showed
a positive relationship to histological grading and muscle
invasion [13].
Epidermal growth factor receptor (EGFR) is a member of
the tyrosine kinase receptor family, a group of receptors
which are all encoded by the c-erbB oncogenes. It is situ-
ated on chromosome 7 and is a 170 kDa protein that con-
sists of three distinct structural parts. It has been proved
that epidermal growth factor signaling plays a pivotal role
in tumorigenesis and disease progression. Overexpression
of EGFR leads to uncontrolled cell proliferation, increased
angiogenesis and reduced apoptosis, processes necessary
for continuing malignant growth [14]. The role of EGFR in
urothelial tumors was supported by the observation that
40%–60% of human bladder tumors overexpress EGFR
mRNA and protein [15]. In addition, some studies
showed a strong correlation between EGFR positivity and
high grade, late stage, tumor progression and poor clinical
outcome in the classic TCC of the bladder [16-18].
The present study was conducted to assess the prognostic
impact of altered expression of nm23-H1, EGFR,Rb and
p53 gene status either singular or in combination in Egyp-
tian cases of muscle invasive-BBC (MI-BBC). Aberrations
involving these markers will be correlated to the standard
prognostic factors of bladder cancer, patients' response to
treatment, and overall survival (OS).
Methods
Patients and tissue samples
The study included 59 cystectomy specimens obtained
from operable cases of MI-BBC that were diagnosed and
treated at the National Cancer Institute (NCI), Cairo Uni-
versity during the years 1996–1999. From each case, a sec-
tion was obtained from the paraffin block of the tumor,
stained with hematoxylin and eosin and examined under
microscope by two independent pathologists (MNM &
BAA) to confirm the diagnosis, typing and grading of the
tumor as well as to calculate tumor: normal ratio. Only
cases in which the neoplastic cells constituted ≥ 75% were
included in the study. Also included are 15 normal
urothelial tissue samples which were used as a control.
These were obtained from morphologically normal areas
as far away as possible from tumors not exceeding 1.5 cm
in diameter and were confirmed to be normal by micro-
scopic examination of hematoxylin and eosin- stained
slides.
None of the cases have received neo-adjuvant or adjuvant
therapy prior to surgery. All Clinico-pathological data of
the patients including patients' age, sex, tumor type, grade
and stage, lymph node status, local recurrence, distant
metastasis and overall survival (OS) rates were retrospec-
tively collected from the pathology reports and clinical
files of the patients. All studied tumors were graded
according to The World Health Organization (WHO) clas-
sification and staged according to the TNM pathological
staging system [19]. Patients were followed up for local
recurrence (LR), distant metastasis (DM) and overall sur-
vival (OS). The follow-up period ranged from 1–94
months with a median of 19 months. The ethical commit-
tee of the NCI approved the protocol which was in accord-
ance with the ethical guidelines of the 1975 Declaration
of Helsinki.
From each case (tumor and normal), 4 um thick sections
(4) were cut onto positive-charged slides for immunohis-
tochemistry and three 12 um thick sections were cut into
Eppendorf tubes for RNA extraction.
Immunohistochemistry
Sections were deparaffinized in xylene, hydrated through
a series of graded alcohol, washed in distilled water and
0.01 PBS (pH 7.4), immersed in 10 mmol/L citrate buffer
(pH 6.0) and put in a microwave for 5 min at 60°C for
antigen retrieval. Then they were placed in methanol con-BMC Cancer 2009, 9:32 http://www.biomedcentral.com/1471-2407/9/32
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taining 3% H2O2 for 30 min at 4°C to block endogenous
peroxidase activity and incubated with rabbit serum for
10 min to block non-specific antibody binding sites. The
primary antibody was applied at a working concentration
and incubated for 2 hours at 4°C. The monoclonal anti-
bodies used are: antihuman Rb1 (Rb1, 1:80, DAKO), anti-
human nm23-H1 (1:50; Santa Cruz, CA, USA) and anti-
human EGFR (clone H11, 1:50, DAKO). The secondary
antibody and the avidin-biotin complex (ABC) were
applied to slides. Diaminobenzidine (DAB) was used as a
chromogen and sections were counterstained with
Mayer's hematoxylin. Negative controls were obtained by
replacing the primary antibody by non-immunized rabbit
or mouse serum [20].
A distinct brown nuclear staining was scored positive for
Rb. The staining pattern of nm23-H1 was cytoplasmic and
EGFR was membranocytoplasmic. Altered expression of
Rb was defined as absence of nuclear staining in all sec-
tions examined [20]. Evaluation of nm23-H1  was per-
formed as previously described [21]. Cases were scored
negative with < 5% positive cells, +; with ≥ 5%–<25%, ++;
with ≥ 25%–<70%, and +++; with ≥ 70% immunostaining
of tumor cells. The cutoff point for EGFR was 10% and the
intensity of staining was scored as weak; 10–<25%, mod-
erate; 25–<50% and marked >50% (15). At least 500 cells
were counted at 200× magnification.
RNA extraction and PCR amplification
Total RNA was extracted from paraffin-embedded tissue
sections according to the described methodology of pure
script RNA isolation kit, (Gentra, USA). The extracted total
RNA was assessed for degradation, purity and DNA con-
tamination by spectrophotometry and electrophoresis in
1.0% ethidium bromide-stained agarose gel. Reverse tran-
scription (RT) of the isolated total RNA was done using
the Superscript One-Step RT-PCR Kit with Platinum Taq
(Life Technologies, Inc.) in a 50 ul reaction volume con-
taining 1 μl of Superscript II RT enzyme, 2.5 ul 10× RT-
buffer [250 mM Tris-HCl pH8.3, 375 mM KCl, 15 mM
MgCl2], 0.25 μl of 100 mM dithiothreitol, 1 μl of 25 ng
from random primer, 1.5 μl of 10 mM deoxynucleotide
triphosphates, 0.5 μl RNAsin (Promega, USA.), and 1.0 μg
of the extracted total RNA (each sample as well as the con-
trols). Samples were then incubated at 50°C for 60 min,
followed by 4°C until the PCR amplification reaction.
PCR amplification was done as previously described by
Raynor et al. [22] and Ayabe et al. [23]. The primers used
and the PCR conditions for each marker gene are illus-
trated in table 1. Amplification of B-actin gene (621-bp
fragment) was performed to test for the presence of arti-
facts and to asses the quality of RNA. A water control tube
containing all reagents except c-DNA was also included in
each batch of PCR assays to monitor contamination of
genomic DNA in the PCR reagents. Negative RT-PCR con-
trol was used against each sample.
Quantization of the studied genes
Fifteen microliters of each PCR product were separated by
electrophoresis through a 2.0% ethidium bromide-
stained agarose gel and visualized with ultraviolet light.
Gels were video-photographed the bands were scanned as
digital peaks, areas of the peaks were then calculated in
arbitrary units with a digital imaging system (Photo-doc-
umentation system, model IS-1000; Alpha Innotech Co.,
San Leandro, CA, USA). To evaluate the relative expres-
sion levels of target genes in the RT-PCR, the expression
value of the normal pooled urothelial tissues (15 sam-
ples) was used as a normalizing factor and a relative value
was calculated for each target gene amplified in the reac-
tion. Loss of expression in any of the studied genes was
considered if there was a complete absence or more than
a 75% decrease in the intensity of the desired band, in
comparison to the band of normal pooled liver tissue
[24]. Samples were assayed in batches that included both
cases and controls. The absence of bands was verified by
repeating the RT-PCR twice at different days and consist-
ent presence of B-actin gene amplification.
Statistical analysis
Numerical data were expressed as mean ± standard devia-
tion (SD), median, minimum and maximum. Qualitative
data were expressed as frequency and percentage. Chi
square test (Fisher's exact test) was used to examine the
relation between qualitative variables. For quantitative
data, comparison between two groups was done using
Table 1: Primer sequences, expected product size in nucleotides (nt) and PCR conditions for each of the studied marker genes.
Primer Sequences Fragment size PCR conditions
nm23-H1 5'-CGCAGTTCAAACCTAAGCAGCAGCTGG-3'
5'-AGATCCAGTTCTGAGCACAGCTCG-3'
483 bp 95°C for 5 m followed by: 95°C (30s), 55°C(30s), 
72°C(30s) for 32 cycles and 72°C (7 m)
EGFR 5'-TGTGAGGTGGTCCTTGGGAATTTGG-3'
5'-TGCTGACTATGTCCCGCCACTGGA-3'
322 bp 95°C for 5 min followed by: 94°C (1 m), 66°C (1 m), 
72°C (2 m) for 35 cycles and 72°C (7 m)
-actin 5'-ATCTGGCACCACACCTTCTACAATGAGGCTGCG-3'
5'-CGTCATACTCCTGCTTGCTGATCCACATCTGC-3'
838 bp 95°C for 5 min followed by: 94°C (45s), 60°C (45s), 
72°C (2 m) for 35 cycles and 72°C (7 m)BMC Cancer 2009, 9:32 http://www.biomedcentral.com/1471-2407/9/32
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Mann-Whitney test. Survival analysis was done using Kap-
lan-Meier method. The OS duration of the patients was
calculated from the date of diagnosis to the date of death.
Comparison between two survival curves was done using
log-rank test. Probability (p-value) ≤ 0.05 was considered
significant. The multivariate analysis (MVA) was done
using Cox proportional hazard model. Factors entered in
the MVA were significant or of borderline significance in
univariate analysis.
Results
In the present study, 59 well-characterized cases of MI-
BBC were assessed for the expression level and the prog-
nostic value of pRb, nm23, and EGFR proteins as well as
RNA using immunohistochemistry and RT-PCR. The
patients' age ranged from 30–76 years with a median of
50 years, the male: female ratio was 2.47:1.0. Twenty one
out of the 54 patients for whom data regarding metastatic
recurrence was available (38.8%) showed evidence of
recurrence either as local (13), distant (8) or both (5). The
median OS of the patients was 27 ± 6.6 months with the
cumulative OS rate of 56% at 18 months. The presenting
clinicopathological features and survival status of the
whole group of patients are shown in table 2.
Expression of the studied markers
A positive cytoplasmic immunostaining for nm23-H1 as
well as a positive nuclear immunostaining for Rb were
detected in the 15 normal urothelium samples included
in the study as a control. The nm23-H1 positive cells were
restricted to the superficial layer only whereas Rb positiv-
ity was recognized in all layers. On the other hand, no
immunorectivity for p53 or EGFR proteins was detected in
the control samples.
Loss of nm23 protein was detected in 25/59 cases (42.4%)
whereas, positive cytoplasmic immunostaining was evi-
dent in 34/59 (57.6%) cases; 8 of them were minimally
positive and 10 were markedly positive (Figure 1d, e, and
1f). RNA was successfully extracted from 52 out of the 59
cases included in the study whereas in the remaining 7
cases, either no RNA or a degraded RNA was present. This
is explained by the difficulty in obtaining RNA from par-
affin-embedded tissues even with the use of special kits
available. Loss of nm23-H1 RNA was detected in 19/52
(36.5%) of the cases (Figure 2b). The concordance
between the loss of nm23-H1 protein and nm23-H1 RNA
expression was 84.6%.
A positive membranous immunostaining for EGFR pro-
tein was detected in 39/59 (66.1%) cases; 20 of them were
markedly positive, 9 were moderately positive and 10
were minimally positive (Figure 1g). Increased EGFR RNA
was detected in 32 out of the 52 (61.5%) evaluable cases
(Figure 2a). The concordance between the increased
expression of EGFR protein and RNA was 98.1%.
Altered pRb expression, defined as negative nuclear stain-
ing, was detected in 34/59 (57.6%) cases whereas 25 cases
(42.3%) were normal with either homogeneous or heter-
ogeneous nuclear immunostaining (Figures 1b, and 1c).
We have previously assessed the same series of BBC for
p53 protein expression and gene mutations [3]. Positive
nuclear immunostaining for p53 was detected in 21 out of
the 59 cases included in the present study (35.6%); of
which 6 were minimally positive and 15 were markedly
positive (Figure 1a). Mutations of the p53 gene (exons 5
through 10) were detected in 8 cases only (13.6%) with
Table 2: Clinicopathological features of the 59 patients studied
Parameter No of Cases (%)
Sex:
Male 42 (71.2)
Female 17 (28.8)
Pathological Subtype:
SCC 27 (45.8)
TCC 27 (45.8)
Adeno 5 (8.5)
Grade:
I 5 (8.5)
II 39 (66.1)
III 15 (25.4)
Pathological Stage:
P2 3 (5.08)
P3a 24 (40.06)
P3b 26 (44.06)
P4 6 (10.2)
Lymph Node Involvement:
Positive 10 (16.9)
Negative 49 (83.1)
Local recurrence:
No 41 (69.5)
Yes 13 (30.5)*
Metastasis:
Negative 46 (78)
Positive 8 (22.03)*
Outcome:
Dead 32 (54.2)
Alive 27 (45.8)
* Data regarding recurrence and metastasis was available for 54 cases 
onlyBMC Cancer 2009, 9:32 http://www.biomedcentral.com/1471-2407/9/32
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Protein expression of the studied markers in cases of muscle invasive bilharzial bladder cancer Figure 1
Protein expression of the studied markers in cases of muscle invasive bilharzial bladder cancer: Cases of BBC 
showing (a) positive immunostaining for p53, (b) negative immunostainning for Rb, (c) positive heterogeneous immunostaining 
for Rb (d) normal nm23-H1, (e) reduced nm23-H1 expression, (f) loss of nm23-H1 expression in neoplastic cells with positive 
expression in endothelial cells (arrow-positive control), (g) EGFR overexpression.BMC Cancer 2009, 9:32 http://www.biomedcentral.com/1471-2407/9/32
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no mutational hotspots. Four cases showed a single muta-
tional event and 4 revealed several mutations in more
than one exon.
Statistical analysis revealed no significant relation
between the expression level of the studied proteins
except for the highly significant relation between p53 and
EGFR overexpression where 20 out of the 21 (95.2%) p53
positive cases revealed EGFR overexpression while a single
case only (4.8%) showed normal EGFR protein expres-
sion (p < 0.0001).
Correlation between the studied markers and standard 
prognostic factors
As shown in table 3, there was a significant correlation
between positive lymph node status and reduced nm23-
H1 (protein &RNA) (p < 0.0001) and p53 overexpression
(p  = 0.02). Also, there was a significant correlation
between advanced disease stage (p2& p3a vs. p3b& p4)
and reduced nm23-H1  RNA expression (p  = 0.02),
increased EGFR (protein & RNA) (p = 0.003 & 0.01 respec-
tively), altered Rb expression (p = 0.023) and p53 overex-
pression (p  = 0.004). Similarly, there was a significant
correlation between the incidence of recurrence and
increased EGFR RNA (p = 0.003) and a marginally signif-
icant correlation with EGFR protein overexpression (p =
0.064) as well as between metastasis and p53 overexpres-
sion (p < 0.0001), p53 mutation (p = 0.04) and altered Rb
expression (p = 0.026).
Survival analysis
On univariate analysis there was a statistically significant
correlation between reduced OS rates and tumor type
(SCC) (p = 0.043), high tumor grade (p = 0.008), local
recurrence (p  = 0.0001) and distant metastasis (p  =
0.0001). A borderline significance was reported between
RNA expression of EGFR, nm23-H1 and   actin in cases of muscle invasive bilharzial bladder cancer Figure 2
RNA expression of EGFR, nm23-H1 and   actin in cases of muscle invasive bilharzial bladder cancer: (a) Expression 
of EGFR by RT-PCR: first lane; molecular weight marker, lanes 1–7: cases of BBC showing EGFR expression, lane 8: a negative 
control, (b) nm23-H1 RNA expression by RT-PCR: Lanes 1, 2, 8–11: normal expression of nm23-H1, lanes 3 and 6: loss of 
expression of nm23-H1, and lanes 4, 5, and 7: reduced expression of nm23-H1, and (c) Lanes 1–11: Expression of   actin in cases 
of BBC.BMC Cancer 2009, 9:32 http://www.biomedcentral.com/1471-2407/9/32
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advanced disease stage (3b+4 vs 2+3a) and reduced OS.
Similarly reduced OS rates was significantly associated
with loss of nm23-H1 RNA (p = 0.021), increased EGFR
protein (Figure 3a) and EGFR RNA expression (p = 0.034
&p = 0.025) and p53 overexpression (p = 0.011) (Figure
3b). The cumulative survival for cases with normal nm23-
H1 RNA expression was 64.8% whereas it was 35.5% for
cases with reduced/lost nm23-H1  RNA. Likewise, the
cumulative survival for EGFR positive patients was 41.0%
compared to 69.0% for EGFR negative patients and 29%
for patients with p53 overexpression vs 60% for patients
with no overexpression. On the other hand, the cumula-
tive survival for nm23-H1 protein overexpression, altered
Rb and p53 mutation did not differ significantly between
negative and positive groups (p values 0.345, 0.287 and
0.539; respectively). On multivariate analysis, only
increased EGFR expression (protein or RNA), the presence
of metastasis and/or recurrence, a high tumor grade (GII
&GIII) and a combination of aberrant markers (≥ 2) were
significantly associated with reduced OS rates (p  =
0.022&0.025, p = 0.000, p = 0.001, p = 0.001). On the
other hand, p53 overexpression and advanced tumor stage
Table 3: The correlation between aberrant expression level of the studied markers and the clinicopathological features of the patients
Parameter nm23-H1
IHC(25)
nm23-H1
RNA (19)
EGFR
IHC(39)
EGFR
RNA (32)
Rb
IHC(34)
P53
IHC(21)
Age(mean ± SD) 50.2 ± 11 54.o ± 8.6 51.7 ± 11 48.5 ± 10.2 49.5 ± 11.4 53.9 ± 11.3
p value 0.41 0.63 0.73 0. 41 0.144 0.175
Sex
Male (42) 19 13 28 25 22 17
Female (17) 64 1 1 71 24
p value 0.48 0.42 0.88 0.62 0.2 0.22
Pathology:
SCC 14 9 16 9 16 7
TCC 10 8 20 20 16 12
AC 1 2 3 322
P value 0.536 0.661 0.21 0.365 0.85 0.36
Grade:
I 1 2 3 340
II 17 15 25 20 22 16
III 7 2 1 1 985
P value 0.916 0.713 1.0 0.785 0.71 0.224
Stage:
p3a 15 4 26 17 25 17
p3b 9 1 0 7 962
p4 1 5 6 632
P value 0.13 0.02 0.003 0.01 0.023 0.004
Lymp nodes:
Positive 9 6 8 446
Negative 16 13 31 28 30 15
P value <0.0001 <0.0001 0.31 0.431 0.216 0.02
Recurrence:
Negative 16 15 26 24 23 13
Positive 94 1 3 81 18
P value 0.43 0.51 0.06 0.003 0.72 0.347
Metastasis:
Negative 20 15 31 23 30 13
Positive 5 4 8 948
P value 0.75 0.51 0.78 0.511 0.026 <0.0001
SCC = Squamous Cell Carcinoma; TCC = Transitional Cell Carcinoma; Adeno = AdenocarcinomaBMC Cancer 2009, 9:32 http://www.biomedcentral.com/1471-2407/9/32
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Kaplan-Meier analysis for cases of BBC Figure 3
Kaplan-Meier analysis for cases of BBC. Overall survival is significantly lower in patients with: (a) increased EGFR expres-
sion, (b) p53 overexpression, (c) combined (nm23 -ve and EGFR +ve), (d) combined (nm23 -ve and p53 +ve),
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Table 4: Overall survival in relation to standard clinicopathological prognostic factors and the studied markers
Univariate analysis Multivariate analysis
Predictive variables CS HR CI p HR CI p
Age
<47 68% 1 0.99, 1.02 0.880
≥ 47 * 66%
Sex:
Male (42) 59% 1.1 0.85, 1.04 0.652
Female (17) 64%
Tumor type
SCC (27) 60% 1.212, 0.538, 2.734 0.643
TCC (27) 65%
Adenocarcinoma (5) 60%
Tumor grade
I (5) 66% 1.96 1.66, 21.331 <0.000 4.350 1.786, 10.591 0.001
II (39) 32%
III (15) 11%
Lymph Node Involvement: 1.099 0.423, 2.859 0.846
Positive (10) 49%
Negative (49) 55%
Metastatic recurrence:
No (33) 58% 14.149 5.117, 39.123 0.000 14.903 5.315, 41.785 0.000
Yes (21) 25%
Pathological Stage:
p2 & pp3a (27) 49% 1.341 0.575, 3.127 0.498
p3b &p4 (32) 35%
Nm23 (IHC)
Positive (34) 66.5% 1.62 0.535, 2.244 0.345
Negative (25) 59.6%
nm23(RNA)
Positive (33) 64.8% 1.34 1.20, 1.50 0.021 0.695 0.586, 1.975 0.444
Negative (19) 35.5%
EGFR (IHC)
Positive (39) 41% 1.61 1.04, 2.29 0.034 3.576 1.206, 10.602 0.022
Negative (20) 69%
EGFR (RNA)
Positive (32) 39% 1.69 1.16, 2.74 0.031 3.911 1.148, 8.511 0.025
Negative (20) 69%
Rb
Positive (25) 54% 1.1 0.27, 1.76 0.287
Negative (34) 49%
p53 (IHC)
Positive (21) 29% 3.9 2.281, 12.42 0.011 2.512 0.948, 6.662 0.64
Negative (38) 60%
P53 (mutations)
Positive (8) 0.539BMC Cancer 2009, 9:32 http://www.biomedcentral.com/1471-2407/9/32
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(3b &4 vs 2&3a) showed a borderline significance (table
4)
The OS rates were also assessed in relation to combined
genetic aberrations involving more than one gene (Table
5). Cumulative survival for altered expression of nm23-H1
and p53 (combined) was 11.0% as compared to 57.0% for
other combinations (p = 0.0004), while that for altered
expression of nm23-H1 and EGFR (combined) was 28.0%
as compared to 60.0% for other combinations (p  =
0.029). The cumulative survival for altered expression of
EGFR and p53 (combined) was 18.0% as compared to
58% for other combinations (p = 0.0002) (Figure 3c–e).
However, combined nm23-H1 loss and altered Rb, altered
Rb and p53 overexpression as well as altered Rb and EGFR
overexpression did not show an impact on survival (p =
0.438, 0.174, and 0.875; respectively). A statistically sig-
nificant correlation was also present between OS and
aberrations involving the 4 studied markers (p = 0.0001).
Discussion and Conclusion
Molecular studies of bladder tumors have identified sev-
eral genetic alterations including self insufficiency in
growth signals, evasion of apoptosis, sustained angiogen-
esis, acquisition of indefinite replication potential and
metastasis. However, only few of these have proven to be
potentially positive clinical targets in the prognosis and
therapy of bladder cancer [25].
The present study addresses, for the first time, the role of
nm23-H1 and EGFR aberrations (at the RNA and protein
levels) in Egyptian cases of muscle invasive BBC in rela-
tion to RB, and p53 and illustrates the clinical significance
of these aberrations either singular or in combination.
Reduced expression of nm23-H1  protein and nm23-H1
RNA was significantly associated with positive lymph
nodes, advanced disease stage (p3a vs  p3b&p4) and
reduced overall survival (OS) rates. Taken together, it
could be suggested that, nm23-H1 may be a suppressor for
BBC progression like in some tumors of other organs e.g.
breast, liver, stomach, ovary, and colon [21,26-28].
Data regarding nm23-H1 in TCC of the bladder in western
countries are contradictory. Our results are consistent
with several studies [12,29-31] which showed a signifi-
cantly inverse correlation between reduced nm23-H1
expression and disease staging, histopathologic differenti-
ation, tumor size, high risk of metastasis and reduced OS.
However, some reports showed a positive correlation
between nm23-H1 expression and tumor grading, muscle
invasion or proliferating cell nuclear antigen expression,
implying a positive growth regulatory role for nm23-H1 in
bladder carcinogenesis [13,31,32].
This discordance in the reported results may be partly
explained by differential specificity of the antibodies
Table 5: Correlation between survival and combined marker expression
No. Cumulative survival (%) Median ± SE 95% CI p. value
Nm23(-)&p53(+) 9 11 6 ± 1.49 3.08 – 8.92
Other combinations 50 57 43 ± - - 0.0004
Nm23(-)&EGFR(+) 18 28 10 ± 3.18 3.76 – 16.24
Other combinations 41 60 43 ± - - 0.029
EGFR(+)&p53(+) 11 18 6 ± 3.85 0 – 13.55
Other combinations 48 58 43 ± - - 0.0002
Nm23(-), p53(+),EGFR(+) 6 15 5.8 ± 3.85 0.1–13.55 0.0001
Other combinations 53 59 43 ± - -
Nm23(-), p53(+),EGFR(+)&b (-) 7 9 4 ± 5.62 1.45 – 20.21 <0.0001
Other combinations 52 58 50 ± - -
Negative (51)
Number of abnormal genes 1.70 1.20, 5.90 0.022 7.331 2.696, 12.940 0.001
<2
≥ 2
* The median age for the studied patients
** Data regarding metastatic recurrence was available for 54 cases only
Table 4: Overall survival in relation to standard clinicopathological prognostic factors and the studied markers (Continued)BMC Cancer 2009, 9:32 http://www.biomedcentral.com/1471-2407/9/32
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applied in the earlier reports. In our work as well as that
of Chow and co workers [29], a monoclonal antibody
reactive to purified nm23-H1 of human origin was used,
whereas polyclonal nm23-H1 antibody [12,31] and mon-
oclonal anti-NDP (nucleoside diphosphate) kinase anti-
body [32] were used in some prior studies. With respect to
NDP kinase, the enzyme activity has been proved to be
unrelated to tumor suppression [33]. The high sensitivity
and specificity of the monoclonal antibody used in the
present study was confirmed by the 100% concordance
reported between the protein and RNA expression levels.
Our results regarding the frequency of increased EGFR
expression (62.3% and 66.1%; protein and RNA respec-
tively) is within the universally reported range (60–75%)
in non- bilharzial bladder cancer cases [34,35]. In BBC,
the role of EGFR was addressed in two studies only. In the
first study [20], EGFR overexpression was detected in 67%
of the cases with no significant relation reported with any
of the clinicopathological prognostic factors or survival.
In the second study (36) the authors reported EGFR loss
in high grade SCC but not TCC.
We also found that increased expression of EGFR protein
and/or RNA were significantly associated with advanced
disease stage, increased incidence of local recurrence and
reduced OS. The significant association reported in the
current study between increased EGFR  expression and
high tumor stage is in agreement with several previous
studies on TCC of the western countries [34,36]. How-
ever, Popove et al [16] demonstrated that EGFR expres-
sion had no additional prognostic value over clinical
stage, grade or cell proliferation. The study of Memon et
al. [37], provided an explanation for this controversial
data since they found that in some cases EGFR expression
alone shows no correlation with survival, yet a high
expression of EGFR  together with increased Her3  and
Her4  correlate with a better survival compared to
increased EGFR together with decreased Her3 and Her4.
This denotes the existence of a cooperative/synergistic
effect between EGFR  and other ERB  family members
mainly Her3/4.
In a recent study, Calquhom et al. [38] found a trend
towards improved bladder cancer-specific survival in
EGFR negative patients. Moreover, a positive response to
radiotherapy significantly correlated with a negative EGFR
status in the studied patients. Similarly Munk et al. [39]
illustrated that EGFR activation induces cell survival in
RT4 and T24 bladder cancer cell lines treated with DNA
damaging chemotherapeutic agents. Therefore, they con-
cluded that combined treatment with these drugs and
EGFR inhibitors might improve the efficacy of bladder
cancer treatment.
Numerous studies have claimed that inactivation of p53
and Rb plays a pivotal role in the pathogenesis of BBC and
none bilharzial bladder cancer [5,9,40-42]. Our results are
similar to those of Loachim et al. [43] who found altered
expression of Rb and p53 proteins in 55.2% and 33.3% of
their studied cases. On the other hand most previous stud-
ies reported lower rates, varying from 16–39% for Rb
expression. These studies included either superficial blad-
der tumors only [41] or a mixture of superficial and mus-
cle invasive tumors [5,42], whereas the present study
includs muscle invasive tumors only. The higher fre-
quency found in BBC cases could also be explained by the
high frequency of HPV infection (46%–100%) reported
by several investigators in Egyptian cases of BBC
[3,44,45].
The clinical significance of Rb loss is still conflicting. Our
results are consistent with some previous studies [42,46]
which showed that Rb negative tumors had a more aggres-
sive biologic behavior with decreased patients' survival,
and more liability to tumor progression than positive
ones. Thus loss of Rb expression can be used as a prognos-
tic factor in bladder cancer. However, some other studies
found no correlation between altered Rb expression and
any of the known prognostic variables [5,47].
Our results regarding p53 mutation and/or protein over-
expression in BBC and its prognostic value are compara-
ble to previous reports on BBC and some non bilharzial
bladder cancer [3,5,7,44]. However, our frequency is
lower than Helal et al [48] who detected p53 overexpres-
sion in 52% of in non bilharzial bladder cancer cases and
in and 56.3% of BBC cases. The difference between our
results and those of Helal et al [48] could be attributed to
the presence of associated HPV infection in our studied
cases which lead to degradation of the p53 protein (3)
whereas Helal et al. were not able to find HPV-DNA by in
situ hybridization in their studied cases. The prognostic
value of p53 which was reported in the current study has
been previously reported in several studies on bladder
cancer [3,42,46,49].
An interesting and novel finding in the present study is the
correlation between aberrant expression of the studied
markers and the OS rates and the use of marker combina-
tion for the assessment of the clinical outcome of patients.
According to our data patients were categorized into two
groups with a statistically significant difference between
these groups with respect to OS rates: patients with aber-
rations in a single gene and those with more than one
abnormal gene (Tables 4&5). This denotes the signifi-
cance of using a panel of genes for predicting patient's
outcome rather than using a single gene. Similar results
have been reported by Shariat et al. [42] who found in
their study of superficial cases of TCC of the bladder thatBMC Cancer 2009, 9:32 http://www.biomedcentral.com/1471-2407/9/32
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a combination of biomarkers (p53, Rb, p21 and p27) are
useful in stratifying patients into different risk groups for
disease recurrence and progression.
We conclude that aberrant expression of nm23-H1, EGFR,
p53 and RB is a frequent event in BBC. A high EGFR and
p53  expression could be added to the existing clinico-
pathologic prognostic factors. Moreover, a combination
of these markers or some of them has synergistic effects in
stratifying patients into different risk groups: those with
more than one abnormal gene have a higher risk of dis-
ease progression and a reduced OS whereas those with a
single abnormal gene have a better clinical outcome and
OS rates.
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